<DOC>
	<DOC>NCT03097861</DOC>
	<brief_summary>To evaluate the bioequivalence of sprinkle and capsule formulations of lubiprostone, as compared to placebo, when administered orally in subjects with CIC.</brief_summary>
	<brief_title>Evaluation of the Bioequivalence of Sprinkle and Capsule Formulations of Lubiprostone, as Compared to Placebo</brief_title>
	<detailed_description />
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Lubiprostone</mesh_term>
	<criteria>Subject either has medicallyconfirmed diagnosis of chronic constipation (per Rome III), or meets the diagnosis as confirmed using the Rome III constipation module questionnaire during the Screening period. Subject is male or female, 18 or older years of age Subject must be on stable dose of fiber supplement or a concomitant medication for the indication of lowering blood pressure Subject has any gastrointestinal (GI) condition, other than constipation, affecting GI motility or defecation. Subject is unable to eat or drink, take oral medications, or to hold down oral medications due to vomiting</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>